Peter J. Goebell

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma

Sunanda Chatterjee, Ram H. Datar, David Youssefzadeh et al. · Journal of Clinical Oncology · 2004 · 257 citations · Full text

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

Tomonori Habuchi, Michael Marberger, Michael J. Droller et al. · Urology · 2005 · 167 citations

Prognostic Biomarkers, Urology, Genitourinary Cancer +6

The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents

Pauline Dürr, Katja Schlichtig, Carolin Kelz et al. · Journal of Clinical Oncology · 2021 · 96 citations · Full text

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer

Sunanda Chatterjee, Ben George, Peter J. Goebell et al. · The Journal of Pathology · 2004 · 91 citations